{"version":"https://jsonfeed.org/version/1.1","title":"Healthcare briefings","description":"Healthcare, biotech, medtech, reimbursement, and hospital-operations coverage only where AI, technology, policy, or market structure is part of the story. Informational only; not medical advice.","home_page_url":"https://guidances.org/topic/healthcare","feed_url":"https://guidances.org/topic/healthcare/feed.json","language":"en","mock_mode":false,"items":[{"id":"388bda20-10a8-410f-b9d6-9465830bf53a","url":"https://guidances.org/en/article/388bda20-10a8-410f-b9d6-9465830bf53a/fda-s-ai-ml-device-rulebook-how-premarket-submissions-shape-the-entire-m-34d31fb3","title":"FDA's AI/ML Device Rulebook: How Premarket Submissions Shape the Medtech Commercial Chain","summary":"The FDA's regulatory framework for AI/ML-enabled medical devices is an important checkpoint that precedes downstream commercial decisions such as reimbursement, hospital procurement, and clinical integration. For SaMD developers, medtech investors, and hospital operators, understanding how premarket submissions work and where the agency's evolving policy stands is essential to mapping realistic go-to-market timelines.","date_published":"2026-06-28T08:47:08.933+00:00","date_modified":"2026-08-05T05:36:09.157947+00:00","tags":["healthcare","FDA AI medical devices","AI ML enabled medical devices regulation","Software as a Medical Device SaMD","premarket submission AI","CMS reimbursement AI devices","Predetermined Change Control Plan PCCP","medtech AI regulatory framework","510k De Novo PMA AI","FDA SaMD policy","AI diagnostics market entry","clinical decision support regulation","AI medical device approval process","healthcare AI policy 2026","FDA AI ML guidance","adaptive algorithm medical device"],"external_url":"https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices"},{"id":"52f6c9e3-5599-4d4e-8c4e-98e34de2f631","url":"https://guidances.org/en/article/52f6c9e3-5599-4d4e-8c4e-98e34de2f631/fda-cdrh-reframes-medical-device-commercialization-around-payment-and-ca-3cfd8947","title":"FDA CDRH Reframes Medical Device Commercialization Around Payment and Capital Risk","summary":"The FDA’s Center for Devices and Radiological Health has put financing and reimbursement on its FY2026 research agenda, highlighting that regulatory clearance alone does not determine commercialization. The signal is especially relevant for AI-enabled software devices and early-stage health-tech builders that still face a gap between technical validation and payer acceptance.","date_published":"2026-06-27T15:12:17.655+00:00","date_modified":"2026-07-11T13:40:47.709121+00:00","tags":["healthcare","FDA CDRH","medical device reimbursement","medical device financing","AI medical device policy","health tech commercialization","CMS coverage","digital diagnostics","clinical decision support","reimbursement research","FY2026 BAA","medtech policy","health economics","hospital procurement","software as a medical device","payment pathway"],"external_url":"https://www.fda.gov/media/191147/download"},{"id":"b445a575-f56d-47dc-8e80-878dfb532926","url":"https://guidances.org/en/article/b445a575-f56d-47dc-8e80-878dfb532926/fda-s-pccp-framework-and-the-reimbursement-gap-what-ai-health-device-fou-6a63668b","title":"FDA's PCCP Framework and the Reimbursement Gap: What AI Health Device Founders Must Resolve Before Clearance Means Revenue","summary":"The FDA's January 2025 draft guidance on AI-enabled device software lifecycle management introduces a Predetermined Change Control Plan and ongoing real-world monitoring obligations that restructure the compliance economics for digital health startups. A noted FDA-CMS collaboration on Medicare coverage for digital behavioral health tools adds a second, unresolved policy layer that determines whether regulatory clearance translates into actual revenue.","date_published":"2026-06-26T23:29:47.431+00:00","date_modified":"2026-07-04T00:00:49.716334+00:00","tags":["healthcare","FDA AI device lifecycle management","Predetermined Change Control Plan PCCP","AI-enabled medical device software","digital health reimbursement gap","FDA CMS Medicare collaboration","generative AI mental health device regulation","real-world performance monitoring FDA","Digital Health Advisory Committee DHAC","AI device marketing submission 2025","digital behavioral health billing codes"],"external_url":"https://www.fda.gov/media/190450/download"},{"id":"97190511-645d-41bb-b306-a8c8b4245715","url":"https://guidances.org/en/article/97190511-645d-41bb-b306-a8c8b4245715/the-billing-code-bottleneck-how-cms-payment-architecture-shapes-the-heal-797f9a8f","title":"The Billing Code Bottleneck: How CMS Payment Architecture Shapes the Healthcare AI Market","summary":"A peer-reviewed analysis in a Nature Portfolio journal documents a structural mismatch at the heart of healthcare AI commercialization: the FDA has authorized hundreds of AI-enabled medical devices for market use, yet CMS payment coverage extends to only a small fraction through AI-specific billing mechanisms. With no formal CMS guidance on AI coverage standards yet finalized, the reimbursement architecture—not regulatory clearance—is the operative constraint on sector growth.","date_published":"2026-06-26T14:12:18.152+00:00","date_modified":"2026-07-11T11:54:26.11125+00:00","tags":["healthcare","healthcare AI reimbursement","CMS AI coverage gap","FDA cleared AI medical devices","NTAP medical AI eligibility","CPT codes AI tools","digital health commercialization","software as a medical device reimbursement","medtech AI policy","AI medical device payment pathway","local coverage determination AI","healthcare AI market structure","CMS AI guidance"],"external_url":"https://www.nature.com/articles/s41746-022-00609-6"},{"id":"42052e40-1e14-4c0f-9fff-377c274a19b1","url":"https://guidances.org/en/article/42052e40-1e14-4c0f-9fff-377c274a19b1/fda-approved-ai-medical-devices-what-payment-patterns-say-about-commerci-091edecb","title":"FDA-Approved AI Medical Devices: What Payment Patterns Suggest About Commercialization Friction","summary":"A peer-reviewed study indexed on PubMed Central reports that industry payments tied to FDA-approved AI medical devices totaled $59.3 million from 2017 through 2023. The money was concentrated in technology-heavy specialties and at larger teaching hospitals, while AIMDs’ share of total device-related payments rose from 0.43% to 1.01%. The pattern is less about headline size than about where adoption begins, and where reimbursement still lags commercialization.","date_published":"2026-06-26T08:03:36.07+00:00","date_modified":"2026-07-04T06:04:53.536279+00:00","tags":["healthcare","FDA-approved AI medical devices","industry payments","Open Payments","CMS reimbursement","medtech commercialization","digital health adoption","teaching hospitals","technology-intensive specialties","AI medical device policy","healthcare market context","clinical AI workflow","reimbursement friction"],"external_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12679402"},{"id":"d099a104-0b89-4129-ae60-2dafb8bec6bf","url":"https://guidances.org/en/article/d099a104-0b89-4129-ae60-2dafb8bec6bf/fda-cms-coordination-on-digital-health-the-reimbursement-bottleneck-that-d9ec3afa","title":"FDA–CMS Coordination on Digital Health: The Reimbursement Bottleneck That Shapes AI Medical Software Markets","summary":"The FDA's Digital Health Center of Excellence maintains active guidance on AI and machine-learning software, and an April 2026 update references the Tempo pilot operating under CMS CMMI's access model. The policy signal is not about a single product clearance; it is about whether the regulatory and reimbursement rails for AI-enabled medical software are being built in parallel — a structural question that can shape commercial timelines across the digital health sector.","date_published":"2026-06-26T07:00:13.722+00:00","date_modified":"2026-07-03T03:49:49.639985+00:00","tags":["healthcare","FDA Digital Health Center of Excellence","CMS CMMI access model","Tempo pilot digital health","AI ML medical software regulation","digital health reimbursement","medical device software governance","healthcare IT policy 2026","SaMD regulatory pathway","digital health commercialization","FDA CMS coordination"],"external_url":"https://www.fda.gov/medical-devices/digital-health-center-excellence"},{"id":"47a5e574-a64d-456f-86f6-2f51ca566ff8","url":"https://guidances.org/en/article/47a5e574-a64d-456f-86f6-2f51ca566ff8/fda-s-ai-ml-medical-device-guidance-what-continuous-performance-monitori-c95457f0","title":"FDA's AI/ML Medical Device Guidance: What Continuous Performance Monitoring Means for Medtech Operators and Builders","summary":"The FDA has updated its guidance framework for AI- and machine-learning-enabled medical devices, centering on validation, transparency requirements, and ongoing real-world performance monitoring. Although the source page date is unverified, the FDA's Digital Health Center of Excellence page remains the authoritative reference for medtech AI compliance. For operators and founders building clinical AI, designing with post-market monitoring in mind can affect product architecture and data infrastructure.","date_published":"2026-06-21T15:55:13.244+00:00","date_modified":"2026-07-08T00:40:44.858615+00:00","tags":["healthcare","FDA AI medical devices","machine learning medical device guidance","FDA Digital Health Center of Excellence","AI ML SaMD regulation","real-world performance monitoring medtech","predetermined change control plan FDA","post-market surveillance AI devices","medtech AI compliance 2026","FDA AI transparency requirements","clinical AI regulatory framework","digital health FDA guidance","AI medical device validation","FDA AI/ML SaMD","healthcare AI regulation","medtech AI market implications"],"external_url":"https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device"},{"id":"d70a92b2-bcab-4144-8cf5-246226cc7131","url":"https://guidances.org/en/article/d70a92b2-bcab-4144-8cf5-246226cc7131/cms-reviews-reimbursement-models-for-ai-diagnostics-in-oncology-a-policy-d749ae72","title":"CMS Reviews Reimbursement Models for AI Diagnostics in Oncology: A Policy Signal for Medtech Commercialization","summary":"The Centers for Medicare & Medicaid Services is examining new reimbursement frameworks for AI-driven diagnostic tools in oncology. The source describes exploratory discussions rather than a final rule, and the provider-supplied May 2024 date is only an unverified recency hint. The issue matters because it sits at the junction of FDA authorization, CMS coverage, and the commercialization path for medtech AI products.","date_published":"2026-06-21T15:55:12.919+00:00","date_modified":"2026-07-18T12:39:36.856314+00:00","tags":["healthcare","CMS reimbursement AI diagnostics","oncology AI medtech policy","Medicare AI diagnostic tools","AI diagnostic reimbursement framework","CMS physician fee schedule AI","medtech AI commercialization","FDA CMS parallel review AI","AI oncology diagnostics market","SaMD reimbursement pathway","digital health CMS coverage","CMS AI 급여","종양학 AI 진단 정책","메드텍 AI 상업화","의료 AI 급여 체계"],"external_url":"https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?ncaid=309&proposed=N"},{"id":"fe79dd06-a934-4ed6-b238-52f5c6aa4dbe","url":"https://guidances.org/en/article/fe79dd06-a934-4ed6-b238-52f5c6aa4dbe/fda-draft-ai-device-guidance-could-reshape-the-cost-structure-of-healthc-32b0d675","title":"FDA Draft AI Device Guidance Could Reshape the Cost Structure of Healthcare Software","summary":"The U.S. Food and Drug Administration has issued draft guidance for developers of AI-enabled medical devices and is seeking public comment through April 7, 2025. Based on the available snippet, the draft spans the full product life cycle, from design and development to maintenance, documentation, and post-market performance oversight. The important issue is not merely regulatory clarity in the abstract, but how that clarity could reallocate operating costs toward data governance, quality systems, and post-launch monitoring. That matters for digital health companies, software-based device developers, hospital procurement processes, and the disclosure language of listed health-tech firms. Still, the verified record here is limited to the FDA announcement snippet, so specific obligations and company-level effects should be treated cautiously until the full draft and subsequent disclosures are reviewed. This article is market context only, not investment advice or medical advice.","date_published":"2026-06-19T08:05:07.498+00:00","date_modified":"2026-07-18T15:54:08.649188+00:00","tags":["healthcare","FDA AI medical devices","FDA draft guidance","AI-enabled medical devices","healthcare AI regulation","medical device software","post-market performance monitoring","digital health compliance","FDA public comment April 7 2025","AI medical device developers","healthcare software regulation"],"external_url":"https://www.fda.gov/news-events/press-announcements/fda-issues-comprehensive-draft-guidance-developers-artificial-intelligence-enabled-medical-devices"},{"id":"cfe9fe5a-567b-419a-b2dc-bab5cf580513","url":"https://guidances.org/en/article/cfe9fe5a-567b-419a-b2dc-bab5cf580513/glp-1-obesity-drugs-show-promise-in-boosting-testosterone-and-sperm-qual-b0559e8e","title":"GLP-1 Obesity Drugs May Be Associated With Testosterone and Sperm Quality Indicators in Men, Endocrine Society Review Suggests","summary":"A systematic review presented at the Endocrine Society's annual meeting in Chicago suggests that GLP-1 receptor agonists may be associated with testosterone levels and sperm quality indicators in men with obesity. The findings are early-stage and require further validation. This article is not medical advice and not investment advice.","date_published":"2026-06-17T03:10:51.645+00:00","date_modified":"2026-08-06T09:17:38.89191+00:00","tags":["healthcare","GLP-1 drugs","testosterone","sperm quality","male reproductive health","obesity treatment","Endocrine Society","pharmaceutical development","clinical trials","Novo Nordisk","Eli Lilly","systematic review"],"external_url":"https://www.nature.com/articles/d41586-026-01867-0"},{"id":"14bfbe0d-d381-41ab-a4f5-666d9d7f4137","url":"https://guidances.org/en/article/14bfbe0d-d381-41ab-a4f5-666d9d7f4137/centene-s-buyout-offer-signals-cost-pressure-in-managed-care-as-medicaid-b17d3eb9","title":"Centene offers buyouts to some employees as managed care faces higher medical costs and policy changes","summary":"Centene has offered buyouts to some employees as it responds to higher medical costs, funding changes, and membership declines. The move highlights how managed-care economics are shaped by Medicaid exposure, ACA and Medicare mix, and policy-driven reimbursement factors.","date_published":"2026-06-16T14:43:34.132+00:00","date_modified":"2026-07-02T18:01:02.547388+00:00","tags":["healthcare","Centene","managed care","Medicaid","health insurance","ACA plans","Medicare","healthcare policy","membership decline","cost cuts","public markets"],"external_url":"https://www.cnbc.com/2026/06/15/centene-to-offer-buyouts-to-some-employees.html"}]}